BioAgilytix Wins Triangle Business Journal’s Life Sciences Award for Early-Stage Product Development Excellence

Durham, NC – [May 28, 2025] – BioAgilytix, a leading global bioanalytical laboratory, has been named a 2025 Life Sciences Award winner by the Triangle Business Journal in the category of Best Early-Stage Product Development Company. BioAgilytix worked on over 40% of new biologic drugs filed with the FDA in 2024 a driving reason the company was recognized at an awards dinner on May 22, 2025, for its commitment to innovation, scientific excellence, and its impact supporting the research and development. 

Headquartered in Durham, North Carolina, BioAgilytix partners with pharmaceutical and biotech organizations around the world to deliver high-quality, regulatory-compliant bioanalytical support from preclinical studies through all clinical trial phases. This award highlights the company’s proven capabilities in supporting large and small molecule drug development beginning at the earliest preclinical phases through post-approval life cycle testing with speed, accuracy, and scientific rigor. 

“This award reflects the hard work, scientific and quality expertise of our global team,” said Davide Molho, CEO of BioAgilytix. “We are honored to be recognized for our role in helping bring innovative therapies to life, starting at the earliest—and often most critical—stages of the development journey.”

Trusted by leading pharmaceutical and biotech companies, BioAgilytix has passed every regulatory audit since its inception—including a recent GLP surveillance audit —with no major regulatory findings, reinforcing its role as a reliable partner in regulated bioanalysis. 

As BioAgilytix continues to invest in advanced technology platforms and scientific talent, the company remains focused on accelerating the development of life-changing treatments through reliable bioanalysis. 

About BioAgilytix

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com. 

For more information, please contact:

Noelle Brawner
Communications Manager
BioAgilytix Labs, LLC
Noelle.brawner@bioagilytix.com